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C9orf72 expansion within astrocytes reduces
metabolic flexibility in amyotrophic lateral
sclerosis
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It is important to understand how the disease process affects the metabolic pathways in amyotrophic lateral sclerosis and whether
these pathways can be manipulated to ameliorate disease progression. To analyse the basis of the metabolic defect in amyotrophic
lateral sclerosis we used a phenotypic metabolic profiling approach. Using fibroblasts and reprogrammed induced astrocytes from
C9orf72 and sporadic amyotrophic lateral sclerosis cases we measured the production rate of reduced nicotinamide adenine
dinucleotides (NADH) from 91 potential energy substrates simultaneously. Our screening approach identified that C9orf72 and
sporadic amyotrophic lateral sclerosis induced astrocytes have distinct metabolic profiles compared to controls and displayed a loss
of metabolic flexibility that was not observed in fibroblast models. This loss of metabolic flexibility, involving defects in adenosine,
fructose and glycogen metabolism, as well as disruptions in the membrane transport of mitochondrial specific energy substrates,
contributed to increased starvation induced toxicity in C9orf72 induced astrocytes. A reduction in glycogen metabolism was
attributed to loss of glycogen phosphorylase and phosphoglucomutase at the protein level in both C9orf72 induced astrocytes
and induced neurons. In addition, we found alterations in the levels of fructose metabolism enzymes and a reduction in the
methylglyoxal removal enzyme GLO1 in both C9orf72 and sporadic models of disease. Our data show that metabolic flexibility
is important in the CNS in times of bioenergetic stress.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an incurable adult
onset disease with a lifetime risk of 1 in 400. The disease,
which involves degeneration of upper and lower motor
neurons, causes muscle paralysis and typically death
within 2–3 years of symptom onset. Historically, the anti-
glutamatergic agent riluzole has been the only available
treatment for ALS, increasing survival by on average
3 months (Bensimon et al., 1994). However, the intraven-
ous free radical scavenger edaravone has now also been
licensed for use in ALS patients in Japan and the USA
(Writing and Edaravone, 2017). It remains crucial to dis-
cover more effective approaches to slow down or stop dis-
ease progression in ALS and extend, not only life
expectancy, but also the quality of life of patients.
One in 10 of all cases of ALS (and of the pathologically-
linked syndrome of frontotemporal dementia) are asso-
ciated with a hexanucleotide repeat expansion (HRE) in
C9orf72, which contributes to neuronal death via
haploinsufﬁciency, dipeptide repeat protein production
and expanded RNA species forming RNA foci (De
Jesus-Hernandez et al., 2011; Mori et al., 2013a, b;
Cooper-Knock et al., 2014) and leads to sequestration of
the nuclear export adaptor SFSR1 and impaired DNA
repair mechanisms (Hautbergue et al., 2017; Walker
et al., 2017). C9orf72 HRE expansions account for a sig-
niﬁcant proportion of both familial and apparently spor-
adic ALS (SALS) patients and not unexpectedly, there are
number of common pathways of dysfunction shared by
both groups of patients including oxidative stress, mito-
chondrial dysfunction, and motor neuron toxicity in vitro
when co-cultured with patient derived astrocytes (Meyer
et al., 2014; Lopez-Gonzalez et al., 2016; Onesto et al.,
2016; Konrad et al., 2017). Furthermore, our group in a
recent publication using a metabolic screening approach,
identiﬁed dysregulation of adenosine metabolism linked to
a loss of adenosine deaminase in C9orf72 and SALS pa-
tient-derived induced astrocytes (Allen et al., 2019).
Both patient subgroups display metabolic dysfunction
which can play a key role in disease progression as meta-
bolic pathways are clearly vulnerable to the disease process
(Haeusler et al., 2016; Tefera and Borges, 2016; De Vos
and Hafezparast, 2017; Vandoorne et al., 2018). Energy
metabolism alterations including insulin resistance, altered
levels of free fatty acids and perturbations in lipid homeo-
stasis including cholesterol metabolism, have been reported
both in patients and animal models of ALS (Dupuis et al.,
2004, 2008; Fergani et al., 2007; Pradat et al., 2010;
Palamiuc et al., 2015). Furthermore, patient hypermetabo-
lism and mitochondrial electron transport chain dysfunc-
tion, coupled with increased reactive oxygen species, can
lead to mitochondrial uncoupling and reduced ATP
output. These metabolic alterations are observed not only
in the CNS, but also in peripheral tissues (Allen et al.,
2003, 2014; Ferraiuolo et al., 2011b; Bartolome et al.,
2013; Raman et al., 2015; Tefera and Borges, 2016).
Fibroblasts are now established as a robust initial model
for studying ALS patient subgroups. Mitochondrial dys-
function, including altered respiratory chain activity and
increased uncoupling, glycolytic upregulation and meta-
bolic gene expression changes, have been recorded in ﬁbro-
blasts grown in culture from sporadic and familial ALS
cases (Allen et al., 2014, 2015; Kirk et al., 2014; Raman
et al., 2015). Fibroblasts isolated from ALS patients with a
SOD1 mutation have reduced mitochondrial respiration,
but can upregulate glycolysis to meet ATP demands, and
ﬁbroblasts isolated from sporadic ALS patients show an
increased dependence on glycolysis with age (Allen et al.,
2014, 2015). Similar glycolytic changes have been observed
in NSC34 cell models of ALS using a metabolomic ap-
proach (Valbuena et al., 2016). This indicates an inherent
metabolic ﬂexibility that, at least from a bioenergetic per-
spective, may allow the cells to initially adapt to the under-
lying disease pathophysiology.
The additional advantage of ﬁbroblasts is that they can
be reprogrammed into induced neuronal progenitor cells
(iNPCs), which can in turn be differentiated into induced
astrocytes. ALS patient-derived induced astrocytes, have
been shown to cause increased toxicity to wild-type
motor neurons when grown in co-culture compared to con-
trol derived induced astrocytes (Meyer et al., 2014).
Astrocytes, along with oligodendrocytes, have a key role
in the metabolic support of motor neurons and have a
signiﬁcant inﬂuence on the rate of disease progression
(Pellerin and Magistretti, 1994; Lin et al., 1998; Clement
et al., 2003; Yamanaka et al., 2008; Ferraiuolo et al.,
2011a, b, 2016; Tefera and Borges, 2016). Given that clin-
ical evidence supports a negative impact of dysfunctional
energy metabolism on the disease progression in ALS
(Desport et al., 2005; Dupuis et al., 2011), it is vital to
understand how ALS affects astrocyte metabolic processes
including metabolic ﬂexibility (the ability of a cell to mo-
bilize and use alternative substrates to meet energy de-
mands). This understanding would offer the potential for
the pathways in question to be manipulated with strategies
to improve bioenergetic output and increase the metabolic
support for motor neurons.
A recent publication from our laboratory used a novel
approach to identify C9orf72-dependent metabolic dys-
functional pathways (Allen et al., 2019). Using both patient
derived ﬁbroblasts and reprogrammed human induced
astrocytes, we used a phenotypic metabolic proﬁling ap-
proach (Bochner et al., 2011; Boccuto et al., 2013) to iden-
tify deﬁcient metabolic pathways. This technology enables
the comparison of normal versus disease model cells by
simultaneously comparing the rates of energy production
from 91 potential energy substrates. This approach had
not been used previously in the ALS ﬁeld and allowed a
non-biased metabolic screen to be performed on C9orf72
cell models to identify novel dysfunctional metabolic path-
ways. We identiﬁed an adenosine metabolic dysfunction in
C9orf72 cell models caused by loss of adenosine
2 | BRAIN 2019: 0; 1–20 S. P. Allen et al.
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deaminase, which was also present in sporadic induced
astrocytes. Bypassing the defect with inosine supplementa-
tion in vitro increased induced astrocyte bioenergetic ﬂux
and ATP levels, as well as reducing astrocyte-mediated
neuronal toxicity. In this present study, we have assessed
the ability of our novel metabolic proﬁling approach to
distinguish between controls and C9orf72 ALS cases
using principal component analysis (PCA). We have used
our novel screening approach to show that induced astro-
cytes from C9orf72 ALS cases display a signiﬁcant reduc-
tion in metabolic ﬂexibility and we have interrogated the
pathways involved in this loss of ﬂexibility. We present for
the ﬁrst time alterations in glycogen metabolism, fructose
metabolism, methylglyoxal detoxiﬁcation and mitochon-
drial substrate transport, which all could contribute to a
loss of metabolic ﬂexibility in C9orf72 astrocytes, making
them vulnerable to starvation-induced cell stress under
times of bioenergetic deﬁcit.
Materials and methods
All chemicals are from Sigma unless stated otherwise.
Human biosamples
Experiments were carried out using samples obtained from six
C9orf72 HRE-positive ALS cases, eight SALS cases and eight
matched controls (Supplementary Table 1). The average age at
time of skin biopsy in ALS cases (seven females, seven males)
was 54 [standard deviation (SD)12.0] years and 55.1 (8.8)
years in controls (six females, three males). The average disease
duration of the ALS cases was 40.0 (21.7) months. The
average age at time of skin biopsy in sporadic Parkinson’s
disease cases (two females) was 53.5 (3.5) years and 53.3
(3.9) years in age matched controls (three males, one female).
Ethical approval
Informed consent was obtained from all human subjects before
skin sample collection (Study number STH16573 and
STH16350, Research Ethics Committee reference 12/YH/
0330). All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were
followed.
Human fibroblast cultures
Sterile skin biopsies were obtained from the forearm of sub-
jects after informed consent, in accordance with guidelines set
by the local ethics committee. Fibroblast cell cultures were es-
tablished at the Shefﬁeld Institute for Translational
Neuroscience. Monolayers of primary ﬁbroblast cell cultures
were routinely maintained in T75 ﬂasks in ﬁbroblast cell cul-
ture medium (Lonza) supplemented with 10% foetal calf
serum (Labtech), 2mM glutamine (Lonza BE17–605E),
50 mg/ml uridine (Sigma U3003), vitamins (Lonza 13–607C
1/100 dilution), amino acids (Lonza BE13–114E 1/100 dilu-
tion), 1mM sodium pyruvate (Lonza BE13–115E) in humid
incubators at 37C supplemented with 5% CO2.
Human induced astrocyte or neuron
culture
Fibroblasts were differentiated as previously described (Meyer
et al., 2014). INPCs were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 1% N2 supplement (Life
Technologies), 1% B27 supplement, 20ng/ml ﬁbroblast growth
factor-2 (Preprotech). INPCs were differentiated into induced
astrocytes on 10cm dishes coated with ﬁbronectin (5mg/ml,
Millipore) by changing the media to DMEM with 10% foetal
bovine serum (FBS) and 0.3% N2 and allowed to differentiate
for 7 days. Induced astrocyte markers of differentiation were
assessed by immunocytochemistry, PCR as described previously
(Meyer et al., 2014; Ferraiuolo et al., 2016) and western blot
analysis. Brieﬂy for immunocytochemistry, 10000 induced
astrocytes were plated in 96-well plates at Day 6 of differenti-
ation and ﬁxed 24h after seeding with 4% paraformaldehyde
(PFA) for 10min and washed three times with phosphate-buf-
fered saline (PBS) before the blocking solution consisting of PBS
with 5% horse serum, 0.05% TritonTM X-100, was applied for
1h. All primary antibodies were diluted in blocking solution and
their dilution and provider are listed as follows: chicken vimen-
tin 1:1000 (Millipore, AB5733), rabbit GFAP 1:1000 (Dako,
Z0334), rabbit CD44 1:200 (Abcam, ab157107) and goat
EAAT2 1:100 (SantaCruz, sc-7760). Incubation of the primary
antibody was performed overnight at 4C. The next day, cells
were washed three times in PBS before the secondary antibodies
at 1:1000 in blocking solution was applied for 1h at room
temperature. Secondary antibodies used included, Alexa Fluor
586 goat -rabbit IgG (H + L) (Invitrogen, A11011), Alexa
Fluor 488 goat -rabbit IgG (H + L) (Invitrogen, A11006)
and Alexa Fluor 488 goat -chicken IgG (H + L) (Invitrogen,
A11039). Hoechst (Hoechst 33342, Trihydrochloride,
Trihydrate, Life Technologies) diluted 1:6000 was added for
5min to visualize the nucleus. Cells were then washed twice
with PBS and imaged using the Opera PhenixTM high-content
imager (PerkinElmer). For quantiﬁcation, all data were uploaded
into Columbus (PerkinElmer), nuclei were detected using
Hoechst 33342 with a size threshold of 30mm2. Cytoplasmic
staining was measured by Alexa 568/488 detection, all intensity
properties were calculated as mean intensity per cell. Ninety-
ninth background intensity was calculated using the secondary
antibody only for each ﬂuorophore and added as a threshold.
Percentage of cells with positive expression was calculated using
the following formula: positive cells / total cell 100. Typically,
all induced astrocytes showed 96–99% expression of all mar-
kers. For differentiation into neurons, iNPCs were plated in a
ﬁbronectin-coated 6-well plate and grown to 70–80% conﬂu-
ence after which iNPC medium was removed and replaced with
neuron differentiation medium (DMEM/F-12 supplemented with
1% N2 and 2% B27). On Day 1 post-differentiation, the cells
were treated with 2.5mM DAPT (Tocris) to promote differenti-
ation toward a neuronal lineage. On Day 3, the medium was
supplemented with 1mM retinoic acid (Sigma), 0.5mM smooth-
ened agonist (SAG) (Millipore) and 2.5mM forskolin (Sigma) for
an additional 7 days.
Phenotype microarray analysis
All assays were performed as described in detail previously
(Allen et al., 2019). Brieﬂy, on Day 1, 96-well phenotype
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microarray plates had 30 ml of IFM-1 (Biolog) containing
10% dialysed FBS and 0.3mM glutamine added, and were
then incubated overnight at 37C/5% CO2. On Day 2, the
IFM-1 ﬂuid, now containing the different metabolites, was
transferred to the corresponding wells on the ﬁbronectin-
coated plates (0.25 mg/ml in PBS). Twenty microlitres of ﬁbro-
blasts at 800 000 cells/ml, or 20 ml of astrocytes at 500 000/
ml were transferred to each well of the substrate plate and
incubated at 37C/5% CO2 for 40 or 24 h, respectively. After
the stated incubation time, 10 ml of redox dye mix MA
(Biolog) was added to each well and the plates sealed with
sterile SealPlate ﬁlm to stop gas transfer. Dye colour change
was measured using a BMG Omega Pherastar at 590/790 nM
for ﬁbroblasts or in an OmniLogTM Phenotype Microarray
system at 37C. All results were normalized to cell number by
addition of CyQUANT (Invitrogen) to each well as per the
manufacturer’s instructions and ﬂuorescence was measured
using a BMG Omega FLUOstar. All astrocyte and ﬁbroblast
cases were analysed in triplicate. All assay data had back-
ground values removed and were normalized to cell number
using Microsoft Excel. Subsequently, PCA plots were gener-
ated using Qlucore Omics Explorer 3.0, with time point
eliminated as a factor and P50.05 taken as signiﬁcant.
Qlucore calculates the eigenvectors (principal components),
which determine the directions of a feature in space, with
the eigenvalues determining the magnitude of separation
and the variation of the data along axes. Qlucore orders
the principal components based on the amount of the total
variance captured by each component, considering all vari-
ables or samples.
Cell survival analysis
Cell survival data were assessed from the CyQUANT readings
taken at the end of each screen and normalizing the speciﬁc
substrate in question to the positive glucose controls as 100%,
using following the equation:
ðCyQUANT value of substrate in questionÞ=
ðaverage CyQUANT value of glucose wellsÞ  100
ð1Þ
Metabolic flexibility analysis
Metabolic ﬂexibility for each cell line was calculated by count-
ing any energy substrates used on the screening plate that
produced NADH within 80% of the NADH production of
the glucose control. Percent of glucose control was calculated
using the following equation:
ðNADH production of energy substrateÞ=
ðglucose control NADH productionÞ  100
ð2Þ
Glucose control NADH production was equal to the average
of the three glucose control wells (B4–B6) on each plate. Only
values within 80% of the glucose control were considered as
20% NADH production was three times the mean standard
deviation (SD) of the background values (A2–A3) on each
plate. Kruskal-Wallis non-parametric analysis was performed
on the values calculated from each plate.
Mitochondrial function assays using
MicroPlateTM substrate plates
For the MicroPlateTM substrate (MFS) assays induced astro-
cytes were harvested as previously described and resuspended
at 666 666 cells/ml in 1Biolog cell suspension medium
(MAS). Thirty microlitres of cell suspension was added to
15 ml 2MAS Buffer (Biolog), 2.5 ml 1.8mg/ml saponin
(Sigma) 2.5 ml water and 10 ml Dye MC (Biolog). This 60 -ml
solution was added to each well of an MFS assay plate
(Supplementary Table 2), which contains 31 metabolites in
triplicate precoated and dried into the wells (rows A–B cyto-
plasmic, rows C–H mitochondrial) plus three negative wells
(no metabolite). The plates were sealed and then incubated
in an OmniLogTM phenotypic microarray system for 6 h for
kinetic analysis. For the mitochondrial substrate analysis,
two-way ANOVA with Sidak post-test correction for multiple
comparisons were performed at every time point. Initial rate
analysis, as well as area under the curve analysis, was per-
formed on all the kinetic traces. For all AUC and rate analysis
see Supplementary Table 3.
Western blot analysis
Three independent ﬂasks of astrocytes were grown to 80%
conﬂuency and harvested as previously described. The cell pel-
lets were washed in PBS and resuspended on ice in 100ml lysis
buffer [89% radio-immunoprecipitation assay (RIPA) buffer
(Sigma), 10% protease inhibitor cocktail (Sigma) and 1%
phosphatase inhibitors (Sigma)]. After 30min, the cells were
centrifuged at 13 000 rpm, 4C for 30min; the supernatant
was collected and retained on ice. Protein content of the super-
natant was determined using a Bradford assay as per the
manufacturer’s instructions. All protein samples were dena-
tured at 95C for 5min in 1Laemmli buffer and 20 mg of
protein was loaded on 10% SDS polyacrylamide gels and pro-
tein electrophoresis was performed using Mini-PROTEAN
Tetra Handcast systems (Bio-Rad). Proteins were resolved
and transferred to a polyvinylidene diﬂuoride membrane
(PVDF, Millipore) at 250 mA for 1 h. The PVDF membranes
were incubated for 1 h with blocking solution containing 5%
BSA in Tris-buffered saline with 0.01% Tween (TBST).
Afterwards, the membranes were incubated overnight at 4C
with the following primary antibodies at 1:1000 dilution in
blocking solution: rabbit actin (Abcam ab8227), rabbit glyco-
gen phosphorylase (Proteintech 12075–1-AP), rabbit phospho-
glucomutase (Proteintech 15161–1-AP), rabbit GLO1
(Proteintech 15140-AP), rabbit GLO2 (Proteintech 17196–1-
AP) rabbit fructokinase, (Proteintech 15681–1-AP), rabbit
aldolase-C (Proteintech 14484–1-AP), mouse pyruvate de-
hydrogenase (Abcam 110330), rabbit pyruvate dehydrogenase
phosphate (Abcam 17746), rabbit vinculin (Abcam 155120),
mouse GLUT1 (Proteintech 66290–1-lg), rabbit GLUT5
(Insight Biotechnology ABP 53119), chicken vimentin
(Millipore AB5733) and rabbit GFAP (Dako, Z0334). Before
detection by chemiluminescence (EZ-ECL HRP kit, Biological
Industries) using a G:BOX (Syngene), the membranes under-
went six 10-min washes in TBST followed by incubation with
secondary anti-rabbit/mouse HRP-linked antibody (1:5000,
Cell Signalling Technology) for 1 h. Quantiﬁcation of protein
4 | BRAIN 2019: 0; 1–20 S. P. Allen et al.
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levels were obtained by densitometry using GeneTools soft-
ware (version 4.03.05, Syngene) to the loading controls.
Quantitative reverse-transcription
polymerase chain reaction
Three independent differentiations of induced astrocytes had
RNA extracted using the RNAeasy Mini kit (Qiagen) and
were DNase treated before being converted to cDNA as
described previously (Hautbergue et al., 2017). The sequences
of all qPCR primers can be found in the Supplementary ma-
terial, Note 1. Quantitative RT-PCR reactions were performed
in duplicate using the Brilliant III Ultra-Fast SYBR Green
QPCR Master Mix (Agilent Technologies) on a CFX 96TM
Real-Time System (Bio-Rad). Quantitative RT-PCR data
were analysed using CFX Manager 3.1 (Bio-Rad) and
GraphPad Prism.
Statistical analysis
All percentage data were ﬁrstly transformed Y = 1/Y, then sub-
sequently Y = logit(Y). To test if the data produced fell under
Gaussian distribution, all data prior to statistical analysis were
assessed for normal distribution by the D’Agostino and
Pearson, the Sharpiro-Wilk and the Kolmogorov–Smirnov nor-
mality tests. If normal, an unpaired t-test or one way ANOVA
with Bonferroni post-test analysis was performed; if not
normal, then a Mann-Whitney or a Kruskal Wallis with
Dunn’s post-test analysis was performed. Statistical analysis
was performed on GraphPad Prism software (version 6.0,
San Diego, CA).
Data availability
Raw data were generated at the University of Shefﬁeld.
Derived data supporting the ﬁndings of this study are available
from the corresponding author on request.
Results
C9orf72 leads to a drop in metabolic
flexibility and reduced cell survival in
iNPC-derived induced astrocytes
Fibroblasts from controls and C9orf72 cases were repro-
grammed into iNPCs and differentiated into induced astro-
cytes. As described previously (Meyer et al., 2014;
Ferraiuolo et al., 2016) both control and C9orf72 induced
astrocytes showed comparable levels of astrocyte markers
by immunocytochemistry, PCR and western analysis.
There was no signiﬁcant difference in the levels of the
astrocyte markers vimentin, GFAP, CD44, EAAT2,
ALDH1L1 and AQP4 in controls and C9orf72 induced
astrocytes (Supplementary Fig. 1A–D), indicating a similar
differentiation status between the two groups. Fibroblasts
and induced astrocytes were then analysed on phenotypic
metabolic array plates (PM-M1, Biolog). This method-
ology allows an unbiased screen of energy substrates that
produce the reduced form of nicotinamide adenine di-
nucleotides (NADH). Each well of the plate contains a
single substrate as an energy source and NADH produc-
tion is monitored by addition of propriety dyes that are
reduced into a coloured product in the presence of NADH.
To assess whether the presence of a C9orf72 expansion
altered the metabolome producing a distinct metabolic
proﬁle compared to controls, we screened ﬁbroblasts and
induced astrocytes from C9orf72 cases and compared them
to healthy controls as described previously (Allen et al.,
2019) and then analysed the data using PCA. As a
C9orf72 expansion also accounts for a signiﬁcant propor-
tion of sporadic ALS cases, we also analysed SALS ﬁbro-
blasts and induced astrocytes in the same way. During the
assay, taking all time points into account, there was sig-
niﬁcant overlap between the two groups in both ﬁbroblasts
and induced astrocytes (Fig. 1A and E). However, we
found better separation between the two groups at later
time points where the greatest variation in the data were
observed (Fig. 1B and F). Therefore, when we focused on
individual time points later in the assay (120min, Fig. 1C
and G; and 300min, Fig. 1D and H), we observed greater
separation, especially in induced astrocytes between the
C9orf72 cases and controls. When we performed the
same experiment using ﬁbroblasts and induced astrocytes
isolated from SALS cases, we observed similar results
(Supplementary Fig. 2). This PCA analysis indicated that
our phenotypic screening approach could be used to iden-
tify distinct metabolic proﬁles in ﬁbroblasts and induced
astrocytes isolated from C9orf72 and SALS cases as
observed previously using classical metabolomic
approaches (Rozen et al., 2005; Blasco et al., 2010,
2014, 2017; Kumar et al., 2010). As the C9orf72 expan-
sion altered the overall metabolic proﬁle, we assessed the
metabolic ﬂexibility of the cell models within our assay by
determining how many of the speciﬁc energy substrates [91
in total including the glucose controls (well ID B4–B6)] the
cells could use and to determine whether the presence of
the C9orf72 expansion inﬂuenced this ﬂexibility. In add-
ition to glucose, control ﬁbroblasts were able to use 10 of
91 substrates (Supplementary Fig. 3A, black points above
dashed line), predominantly using saccharide based metab-
olites, which are located in well IDs A4 to E4 on the x-
axis. When reprogrammed into iNPC-derived induced
astrocytes, this ﬂexibility increased to 16 of 91
(Supplementary Fig. 3A), with a subtle shift in the proﬁle
to the use of nucleoside and carboxylic acid metabolites
(well IDs E10 to G10) as well as saccharides. No loss of
metabolic ﬂexibility was observed in C9orf72 or SALS
ﬁbroblasts compared to controls (Supplementary Fig. 3B
and C). However, when comparing control induced astro-
cytes with C9orf72 induced astrocytes, metabolic ﬂexibility
dropped from 16 to 10 out of 91 (Fig. 2A and C). A
reduction in the overall metabolic ﬂexibility was also
observed in SALS induced astrocytes (Fig. 2B and C).
NADH production correlated with cell survival, as typic-
ally all wells with energy substrates that were used by the
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Figure 1 Cells derived from C9orf72 fibroblast and induced astrocyte cases have an altered metabolic profile. (A) PCA of control
fibroblasts (blue, Con) and C9orf72 fibroblasts (pink C9) at all time points. (B) PCA of fibroblasts coloured for individual time points between
20 and 300min (C) PCA of control fibroblasts (blue, Con) and C9orf72 patient fibroblasts (pink C9) at 120min. (D) PCA of control fibroblasts
(blue, Con) and C9orf72 fibroblasts (pink C9) at 300min. (E) PCA of control induced astrocytes (blue, Con) and C9orf72 induced astrocytes
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cells showed little loss of cell number (Supplementary Fig.
4). In wells where substrates were not used, increased loss
of cell number was observed. The average cell survival
across the plate in ﬁbroblasts was high, 80% for controls,
92% for C9orf72 cases and 80% for SALS cases (Fig. 2D).
However, when reprogrammed to induced astrocytes, aver-
age control survival dropped to 48% (Fig. 2D and
Supplementary Fig. 4A) indicating that metabolic ﬂexibility
was more important in induced astrocytes than ﬁbroblasts
in terms of cell survival. When C9orf72 induced astrocytes
were analysed, ﬂexibility dropped and with it average cell
survival to 23% (Fig. 2D and Supplementary Fig. 4B). In
SALS cases, average cell survival was reduced but this did
not reach signiﬁcance because of one line (Case SALS-17)
being particularly robust compared to the other SALS cases
in terms of metabolic ﬂexibility and cell survival (Fig. 2C,
D and Supplementary Fig. 4C). These data indicate that the
presence of a C9orf72 expansion reduces the metabolic
ﬂexibility of the induced astrocytes, resulting in sensitivity
to starvation induced stress, which may reduce cell num-
bers. This sensitivity was not observed in ﬁbroblast cell
lines.
C9orf72 alters saponin sensitivity in
induced astrocytes and reduces
energy substrate transport
To investigate the loss of metabolic ﬂexibility in the
C9orf72 cases and the starvation-induced toxicity observed
further, we used a mitochondrial functional substrate plate
recently developed by Biolog Inc. These plates use the same
technology as the PM-M1 plates, using a redox dye to
assess levels of reduced NADH in the cell. However, the
plates are coated with 31 cytosolic and mitochondrial me-
tabolites and cells are permeabilized using saponin to allow
transport of the energy substrates into the cell
(Supplementary Table 2). This novel assay allowed us to
determine whether a reduced ability to transport energy
substrates across membranes could contribute to the loss
of metabolic ﬂexibility. Seventeen mitochondrial substrates
from the original PM-M1 plates were also on the MFS
plate, including pyruvic acid, which we observed was hypo-
metabolic in C9orf72 induced astrocytes in our previous
study (Fig. 3A) (Allen et al., 2019). Analysis of NADH
production in the presence of pyruvic acid under saponin
conditions, showed no signiﬁcant difference between con-
trols and C9orf72 induced astrocytes (Fig. 3B). Similar re-
sults were observed with alpha ketoglutaric acid, lactic
acid, malic acid and succinic acid (Supplementary Fig.
5A–H), which were poorly metabolized by C9orf72
induced astrocytes in the initial PM-M1 assays (Allen
et al., 2019) resulting in starvation-like levels of toxicity
(Supplementary Fig. 5J) and therefore at the time were
not considered for further analysis. However, in the pres-
ence of saponin, NADH production in the controls and the
C9orf72 cases were very similar (Supplementary Fig. 5B, D,
F and H), indicating that these substrates were not trans-
ported efﬁciently into the C9orf72 induced astrocytes in the
whole cell assay screen compared to controls. NADH pro-
duction was observed to a sufﬁcient extent in the presence
of seven other metabolites to allow statistical analysis.
However, no differences were observed between C9orf72
and control lines (data not shown). These data indicated
that the presence of the C9orf72 expansion may lead to
alterations in the protein/lipid content of the plasma mem-
brane which may affect metabolite transport. To test this
hypothesis we performed saponin sensitivity assays in
induced astrocytes using the mitochondrial TCA cycle sub-
strates, malic acid and succinic acid with increasing saponin
concentrations. As expected, in the absence of saponin both
the controls and C9orf72 ALS cases metabolised glucose
using the dye which picks up electrons from NADH in
intact cells (dye A; Fig. 3C and Supplementary Fig. 6,
column 1). Unlike the C9orf72 cases, all control lines
could metabolize succinic acid and malic acid giving
higher NADH production (Fig. 3C and Supplementary
Fig. 6). Similar results were observed using the MFS-1
dye (dye C) as a readout (Fig. 3C and Supplementary
Fig. 6, columns 2 and 3).
When increasing levels of saponin were added to the cells
there was a dose dependent increase in NADH production
in the presence of L-malic and succinic acid in C9orf72
induced astrocytes, which peaked at 50–75 mg/ml (Fig. 3D
and Supplementary Figs 5I and 6, columns 3–12). These
data suggested that C9orf72 induced astrocytes, unlike con-
trols, needed the membrane to be more permeabilized (by
the presence of an agent such as saponin) to transport
mitochondrial metabolites into the mitochondria to be
able to use them for energy generation. Taken together,
these data suggest the presence of a C9orf72 expansion
may alter membrane transport of energy substrates.
Figure 1 Continued
(yellow, C9) at all time points. (F) PCA of all induced astrocytes coloured for individual time points between 20 and 300min. (G) PCA of control
induced astrocytes (blue, Con) and C9orf72 induced astrocytes (yellow, C9) at 120min. (H) PCA of control induced astrocytes (blue, Con)
and C9orf72 induced astrocytes (yellow, C9) at 300min. Data are presented as mean of three biological replicates using eight control fibroblasts,
six C9orf72 fibroblasts, three control induced astrocytes and three C9of72 induced astrocytes. Analysis performed on Qlucore with the P-value
set to 40.05. Q-values were 0.113 for control fibroblasts versus C9orf72 and 0.073 for control induced astrocytes versus C9orf72. Percentage
values represent eigenvectors calculated for each analysis. The higher the percentage the greater the confidence of the separation based on
the vector.
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Figure 2 Metabolic flexibility is reduced in C9orf72 induced astrocytes. (A) Metabolic flexibility of control induced astrocytes (orange)
versus C9orf72 induced astrocytes (light blue). (B) Metabolic flexibility of C9orf72 (light blue) versus SALS induced astrocytes (red). Data are
presented as mean with standard deviation of NADH production as per cent of glucose control (well IDs B4–B6). Metabolic flexibility determined
as any energy substrates producing NADH production within 80% of the glucose control. (C) Metabolic flexibility in control, C9orf72 and SALS
induced astrocytes. Data are presented as median with 95% confidence intervals followed by one-way ANOVA with Bonferroni post-test analysis.
(D) Average cell survival in the metabolic profiling assay. Each data point represents cell number in one well of one assay for each ALS case or
control, showing mean and standard deviation. Data were transformed 1 = 1/Y and 1 = logit (Y) prior to Kruskal Wallis with Dunn’s post-test
analysis. The x-axis displays well IDs from the metabolic screening plate (PM-M1), which corresponds to the position on the 96-well plate, A4
through to H12, each well contains a unique energy substrate apart from B4–B6, which all contain the positive control glucose. A1–A3 are the
negative wells and are not included on the graph. *P4 0.05, **P4 0.01, ****P4 0.0001. Astro/iAstrocytes = induced astrocytes; C9 = C9orf72;
con = control; Fib = fibroblasts.
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Figure 3 C9orf72 induced astrocytes have altered saponin sensitivity compared to control induced astrocytes. (A) NADH
production in intact induced astrocytes in the presence of pyruvic acid. Data are presented as mean with standard error followed by two-way
ANOVA with Sidak post-test analysis in combination with area under the curve (AUC) analysis and initial (0–120min) linear regression analysis
(Supplementary Table 3). (B) NADH production in the presence of pyruvic acid with saponin. Data are presented as mean with standard error.
(C) Induced astrocyte NADH production in the presence of glucose (Glu), L-malic acid (Mal) and succinic acid (Succ). A = Dye A; C = Dye C.
Data are presented as mean with standard deviation followed by Kruskal Wallis with Dunn’s post-test analysis. (D) The effect of saponin on L-
malic acid induced NADH production in induced astrocytes. Data are presented as mean with standard deviation followed by one-way ANOVA
with Bonferroni post-test analysis. (E) Kinetic NADH production in induced astrocyte negative wells (no energy substrate present). Data
presented as mean with standard error followed by two-way ANOVA with Sidak post-test analysis in combination with AUC analysis and initial
(0–120min) linear regression analysis (Supplementary Table 3). (F) The effect of starvation on induced astrocyte cell number. Data are presented
as mean with standard deviation. Data were transformed 1 = 1/Y and 1 = logit (Y) prior to Mann-Whitney analysis. *P4 0.05, **P4 0.01,
****P4 0.0001. The arrow in E denotes consecutive significant time points.
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The C9orf72 expansion alters
glycogen mobilization in induced
astrocytes
An additional interesting observation from the saponin
assays was that in all the control lines a noticeable colour
change was observed in the negative (no substrate) wells
(Supplementary Fig. 6, four top wells in column 1) whereas
the C9orf72 cases displayed little colour change. When we
quantiﬁed this, we saw a signiﬁcant difference in NADH
production between controls and C9orf72 induced astro-
cyte lines (Fig. 3C). We also saw similar results in the ori-
ginal screen with a reduction in NADH production in the
no substrate wells in C9orf72 induced astrocytes (Fig. 3E)
and concomitantly increased cell death at the end of the
assay (Fig. 3F). Under conditions of metabolic starvation,
astrocytes rely on the mobilization of internal fuel stores
such as glycogen to meet energy demands. Our previous
publication (Allen et al., 2019) indicated that C9orf72
induced astrocytes showed decreased NADH production
when glycogen was the sole fuel source. This, coupled
with the loss of NADH production under starvation con-
ditions, suggested that the presence of the C9orf72 expan-
sion may lead to a disruption in glycogen mobilization. To
investigate this ﬁnding in more detail we measured the
levels of glycogen phosphorylase (GP) and phosphogluco-
mutase (PGM) in C9orf72 induced astrocytes at the protein
and mRNA levels. A signiﬁcant decrease in both enzymes
at the protein level was observed in C9orf72 ALS lines
compared to controls (Fig. 4A–D), similar results were
observed at the mRNA level (Supplementary Fig. 6D and
E). To determine whether the alteration in glycogen mobil-
ization enzymes was limited to induced astrocytes, we as-
sessed the levels of GP and PGM in induced neurons. The
data indicated that GP levels were reduced in C9orf72 in
induced neurons (Fig. 4E and F), whilst PGM levels were
reduced but to a level that did not reach signiﬁcance
(Fig. 4G and H).
The C9orf72 expansion alters fructose
metabolism and impairs methyl-
glyoxal removal enzymes
As with a glycogen metabolism defect, our previous publi-
cation using this screening methodology detected a reduc-
tion in NADH production in the presence of fructose,
perhaps indicating dysfunction in the fructose metabolism
pathway (Allen et al., 2019). To assess this further, we
measured the levels of fructokinase and aldolase-C, the en-
zymes responsible for metabolism of fructose to fructose 1-
phosphate and then glyceraldehyde, respectively.
Surprisingly we found a modest increase in fructokinase
levels in C9orf72 ALS cases (Fig. 5A and B) although no
increase in aldolase-C was observed (Fig. 5C and D). The
NADH production step from fructose metabolism occurs
downstream of the activity of these two enzymes, when
glyceraldehyde 3-phosphate is converted to 1,3-bisphospho-
glycerate. If the levels of fructokinase and aldolase-C were
unaffected or raised, this suggested a defect further down-
stream perhaps leading to an increase of glyceraldehyde-3-
phosphate (GAP) and dihydroxyacetone phosphate
(DHAP). Fructose is a potent glycating agent, leading to
toxic advanced glycation end products (AGEs) that can
interfere with many cell functions including lipid synthesis,
antioxidant defences, and mitochondrial metabolism.
Disrupted fructose metabolism leads to the generation of
GAP and DHAP, which are both efﬁcient glycating agents
and can be converted to dicarbonyls such as glyoxal and
methylglyoxal, which in turn leads to more stable AGE
production. To combat this, cells have an effective detox-
ifying mechanism that plays a major role in the cellular
defence against glycation and oxidative stress (Thornalley,
1993a, b; Kalapos, 2008a, b). The glyoxalase system con-
tains two sequential enzymatic reactions catalysed by
glyoxalase-1 (GLO1) and glyoxalase-2 (GLO2), using
glutathione as a co-factor. GLO1 converts the hemithioa-
cetal product formed by the reaction of reduced glutathione
with methylglyoxal, to S-D-lactoylglutathione. This com-
pound is then metabolized by GLO2 to D-lactate, which
recycles glutathione. As S-D-lactoylglutathione is non-toxic
GLO1 activity is crucial for methylglyoxal detoxiﬁcation
and determines the rate of AGE formation (Allaman
et al., 2015).
To assess whether levels of these detoxifying enzymes
were altered in C9orf72 induced astrocytes, we measured
protein levels of GLO1 by western blot analysis (Fig. 6A
and B) and mRNA levels by RT-PCR (Supplementary Fig.
7A). We found a signiﬁcant reduction in the levels of
GLO1 in the C9orf72-ALS lines compared to controls.
To assess whether this was limited to induced astrocytes
we measured GLO1 levels in C9orf72 induced neurons
and found a similar reduction (Fig. 6E and F). Although
we found a signiﬁcant reduction of GLO2 at the protein
level in C9orf72 induced astrocytes (Fig. 6C and D) this
was not matched at the mRNA level (Supplementary Fig.
7B) or at the protein level in induced neurons (Fig. 6G and
H).
In a recently published paper, we found similar alter-
ations at the protein level of adenosine deaminase in both
C9orf72 and SALS cases (Allen et al., 2019). As a C9orf72
expansion accounts for a signiﬁcant proportion of sporadic
ALS cases as well as familial cases, we wanted to determine
whether these ﬁndings were limited to C9orf72 ALS cases.
To assess this, we measured the protein levels of glycogen
phosphorylase, PGM, fructokinase, aldolase-C GLO1 and
GLO2 in the three SALS induced astrocytes lines used in
our previous studies and used to generate PCA plots in this
study. Unlike the C9orf72 induced astrocytes no consistent
loss of the glycogen enzymes were observed in SALS
induced astrocytes (Fig. 7A–D). However, as evident from
10 | BRAIN 2019: 0; 1–20 S. P. Allen et al.
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the data (Fig. 7A–D), we observed SALS case-speciﬁc alter-
ations in the glycogen mobilization enzymes. Case SALS-9
had reduced GP compared to controls (Fig. 7A and lowest
three data points in Fig. 7B, unpaired t-test P = 0.032) and
upregulated PGM (Fig. 7C, highest three data points in Fig.
7D, unpaired t-test P = 0.0014), perhaps as a cellular
Figure 4 C9orf72 induced astrocytes and induced neurons have reduced glycogen metabolism enzymes. (A and B) Induced
astrocyte GP levels. (C and D) Induced astrocyte PGM levels. (E and F) Induced neuron GP levels. (G and H) Induced neuron PGM levels.
Densitometry analysis performed by normalizing the protein level of interest to the loading control (actin). Representative western blot of three
controls versus three C9orf72 cases performed n = 3/4 before densitometry analysis followed by a Mann-Whitney (B and D) or an unpaired t-test
(F and H). *P4 0.05. iAstrocytes = induced astrocytes; iNeurons = induced neurons.
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Figure 5 C9orf72 induced astrocytes have altered levels of fructokinase. (A and B) C9orf72 induced astrocyte fructokinase levels (FK).
(C and D) C9orf72 induced astrocyte aldolase-C levels (Ald-C). (E and F) SALS induced astrocyte fructokinase levels. (G and H) SALS induced
astrocyte aldolase-C levels (Ald-C). Densitometry analysis performed by normalizing the protein level of interest to the loading control (actin).
Representative western blot of three controls versus three ALS cases performed n = 3 before densitometry analysis. Data are presented as mean
and standard deviation from three independent biological replicates. All data analysed by an unpaired t-test analysis. *P4 0.05.
iAstrocytes = induced astrocytes.
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response to GP reduction. Case SALS-17 had no change in
GP but showed a mild but signiﬁcant reduction in PGM
levels (unpaired t-test P = 0.041, bottom three data points
in Fig. 7D).
When we assessed the levels of the fructose metabolism
enzymes, the data were very similar to the C9orf72
induced astrocytes. Two out of three SALS cases (Cases
SALS-9 and SALS-12) had raised fructokinase levels but
Figure 6 C9orf72 induced astrocytes and induced neurons have reduced methylglyoxal removal enzymes. (A and B) Induced
astrocyte GLO1 levels. (C and D) Induced astrocyte GLO2 levels. (E and F) Induced neuron GLO1 levels. (G and H) Induced neuron GLO2
levels. Densitometry analysis performed by normalizing the protein level of interest to the loading control (actin). Representative western blot of
three controls versus three C9orf72 cases performed n = 3/4 before densitometry analysis and analysis by an unpaired t-test (B and F) or a Mann-
Whitney test (D). *P4 0.05, **P4 0.01. Lines on blots indicated cropped images. For full length blots, see Supplementary Fig. 8C.
iAstrocytes = induced astrocytes; iNeurons = induced neurons.
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overall no signiﬁcant increase was observed due to the
very low levels of fructokinase in Case SALS-17 (Fig. 5E
and F). As with the C9orf72 induced astrocytes, SALS
cases showed no change in aldolase-C levels (Fig. 5G
and H). Interestingly, when we measured GLO1 levels in
the SALS induced astrocytes, GLO1 was consistently
decreased in all cases, (Fig. 7E and F). However, no dif-
ference was observed with GLO2 (Fig. 7G and H). Similar
results were found at the mRNA level (Supplementary Fig.
7C and D).
Figure 7 SALS induced astrocytes have reduced GLO1 levels. (A and B) Induced astrocyte GP levels. (C andD) Induced astrocyte PGM
levels. (E and F) Induced astrocyte GLO1 levels. (G and H) Induced astrocyte GLO2 levels. Densitometry analysis performed by normalizing the
protein level of interest to the loading control (actin). Representative western blot of three controls versus three SALS cases performed n = 3
before densitometry analysis followed by an unpaired t-tests. **P4 0.01. iAstrocytes = induced astrocytes.
14 | BRAIN 2019: 0; 1–20 S. P. Allen et al.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/b
ra
in
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/b
ra
in
/a
w
z
3
0
2
/5
6
0
6
7
4
9
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 3
0
 O
c
to
b
e
r 2
0
1
9
To conﬁrm the relevance to ALS and to ascertain whether
these alterations were ALS speciﬁc, we assessed the levels of
our target molecules in sporadic Parkinson’s cases and their
age- and sex-matched controls. As with our ALS induced
astrocytes, the sporadic Parkinson’s induced astrocytes
were differentiated from iNPCs that had been reprogrammed
from ﬁbroblasts isolated from sporadic Parkinson’s disease
cases (Supplementary Table 1). No signiﬁcant differences in
the enzymes responsible for fructose metabolism were
observed between the sporadic Parkinson’s disease cases
and their age- and sex-matched controls in either induced
astrocytes or ﬁbroblasts (Supplementary Fig. 7E–H). In
terms of the glycogen enzymes, as with sporadic ALS cases
and unlike our C9orf72 cases, we found no consistent re-
duction in both glycogen enzymes in sporadic Parkinson’s
disease cases. As with our SALS cases we found cell-speciﬁc
levels of both targets, sporadic Parkinson’s disease Case
OB182, for example, had low levels of GP compared to
controls but high levels of PGM (Supplementary Fig. 7E
and G), as observed with Case SALS-9, perhaps again as a
compensatory mechanism.
However, as with our C9orf72 and sporadic ALS
induced astrocytes, we found a consistent signiﬁcant loss
of GLO1 in the sporadic Parkinson’s disease cases com-
pared to the sporadic Parkinson’s disease age and sex
matched controls (Supplementary Fig. 7E and G). These
differences seem to be CNS speciﬁc as when we tested
the original ﬁbroblast lines no differences were observed
(Supplementary Fig. 7F and H). This loss of GLO1 in
both familial and sporadic ALS samples as well as sporadic
Parkinson’s samples may suggest a novel common pathway
of dysfunction between the two neurodegenerative dis-
orders. However, because of the low number of patients
per group further investigation is warranted.
Discussion
Our data show that phenotypic metabolic screening can be
used to distinguish altered metabolic proﬁles between con-
trols and patient-derived, CNS-speciﬁc, ALS models of dis-
ease. We have identiﬁed that induced astrocytes derived
from C9orf72 ALS cases and SALS cases have an altered
metabolic proﬁle compared to controls and display a loss
of metabolic ﬂexibility. Fibroblasts overall showed less sep-
aration from controls than induced astrocytes (Fig. 1 and
Supplementary Fig. 2) and retained their metabolic ﬂexibil-
ity compared to controls. This retained ﬂexibility may be
one factor to explain why ﬁbroblasts are able to compen-
sate metabolically in the presence of genetic alterations that
are injurious for CNS cells such as astrocytes and neurons.
We have previously observed altered metabolic responses in
ﬁbroblasts from both SOD1 and sporadic ALS cases (Allen
et al., 2014, 2015; Raman et al., 2015), but now, with the
adoption of our novel metabolic screening approach, we
can conclude with conﬁdence that inherent metabolic ﬂexi-
bility is vital in the CNS and is reduced in ALS patients.
Our unique approach of screening under non-physio-
logical conditions has allowed us to identify key points in
the metabolic pathway that are affected in C9orf72 induced
astrocytes, which would not have been observed in physio-
logical (non-stress) conditions, including: adenosine metab-
olism, fructose metabolism and glycogen metabolism.
Under times of cellular stress such as the bioenergetic star-
vation induced during the screening process, this loss of
metabolic ﬂexibility contributed to the cell loss observed
in the C9orf72 induced astrocyte model, which was the
result of defects in energy substrate transport, combined
with a reduced ability to mobilize intracellular energy
stores such as glycogen and adenosine to produce NADH
(Figs 3, 4 and Allen et al., 2019).
Glycogen is the main storage form of glucose, mainly
localized in astrocytes in the CNS and can be metabolized
without ATP consumption (Brown, 2004). Decreased
glycogen metabolism, either through reduction of GP and
PGM or -glucosidase (GAA), which has previously been
shown to be reduced at the mRNA level in gene expression
studies on laser captured motor neurons from ALS patients
(Dodge et al., 2013), could lead to glycogen accumulation
in the CNS. At times of high-energy demand or bioener-
getic stress, decreased mobilization of glycogen in ALS
cases may cause decreased glucose levels and therefore
lead to a reduction in ATP production. This has been re-
ported in grey matter neurons and glia of ALS cases and
also in muscle, with glycogen accumulation and diminished
ATP levels observed (Dodge et al., 2013). Laser-captured
astrocytes from SOD1G93A mice have demonstrated a 42-
fold increase in glycogen synthase mRNA (Ferraiuolo et al.,
2011a). However, we found no consistent increase of
glycogen synthase in C9orf72 induced astrocytes at the
protein level (data not shown). Our data suggest a reduced
ability to mobilize glycogen rather than a glycogen storage
defect is likely to contribute to starvation-induced toxicity.
The glycogen defect was more evident in C9orf72 induced
astrocytes, compared to SALS induced astrocytes, which
may indicate a distinct C9orf72 pathogenic mechanism.
However, SALS cases are heterogeneous and ﬁrm conclu-
sions are not yet possible given the relatively small number
of SALS cases used in this study. In addition, the fact that
glycogen level alterations have been observed in tissue from
ALS cases and in SOD1 mice indicates that our ﬁndings are
relevant to the pathogenesis of at least some additional
subtypes of ALS.
Disruption in lysosomal glycogen breakdown, as well as
a secondary defect in the fusion between autophagosomes
and lysosomes, have been implicated in certain myopathies
including Pompe disease. Pompe disease is caused by a mu-
tation in GAA, with deﬁciencies in both humans and in
mouse models leading to accumulation of swollen lyso-
somes swollen containing glycogen (Smith et al., 1967;
Raben et al., 2002, 2009; van der Ploeg and Reuser,
2008). Defects in autophagy are linked with several neuro-
logical disorders including Parkinson’s disease and ALS
(Harris and Rubinsztein, 2011). C9orf72 has been shown
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to play a key role in autophagy initiation, with upregula-
tion of P62 and the LC3 II/I ratio observed in C9orf72
patient-derived cell models indicating an impairment of
autophagy (Webster et al., 2018; Allen et al., 2019). A
key role of autophagy is to release glucose, fatty acids
and amino acids to maintain cellular functions during
stress and starvation. It has been shown in mice, that glyco-
gen-rich fast-twitch muscle ﬁbres induce autophagy to a
greater extent than oxidative slow-twitch ﬁbres
(Mizushima et al., 2004). Therefore, a link may exist be-
tween the glycogen/glucose axis and autophagy regulation
in ALS. C9orf72 autophagy disruption may contribute to
the bioenergetic deﬁcit observed in ALS patients not only in
the CNS but in muscle. Selective targeting of the glycogen/
glucose axis by increasing glycogenolysis could potentially
compensate for the bioenergetic/autophagy defect and in-
crease energy production via glycolysis. This is a crucial
area of metabolic research in ALS, especially in light of
the recent publication suggesting a neuroprotective role of
glycolysis in TDP43-linked ALS (Manzo et al., 2019).
Further mechanistic studies are planned in our laboratory
to uncover the link between C9orf72 hexanucleotide repeat
expansions and glycogen metabolism in ALS.
Substrate mobilization also includes the ability to trans-
port substrates across membranes. We found that C9orf72
induced astrocytes had signiﬁcantly reduced ability to me-
tabolize mitochondrial energy substrates in intact cells,
(Fig. 3 and Supplementary Fig. 5). This resulted in high
levels of toxicity (in the whole cell intact screen), which
were not statistically different from the levels of toxicity
observed under starvation (no energy substrates) conditions
(Supplementary Fig. 5J). This was in contrast to the cyto-
plasmic saccharide based energy substrates identiﬁed, which
in general did not show a starvation like toxicity proﬁle,
with cell numbers signiﬁcantly higher than those observed
under starved, no energy substrate conditions
(Supplementary Fig. 5K). These data indicate that the de-
fects observed in the cytoplasmic saccharide based energy
substrates described in this study and our previously pub-
lished study (Allen et al., 2019) were not due to loss of
energy substrate transport and were due to alterations in
the intracellular enzymes responsible for energy metabolism
in these pathways, which we have identiﬁed. This is in
contrast to pyruvic acid for example, where we saw no
difference in the activation state of pyruvate dehydrogenase
in the C9orf72 induced astrocytes compared to controls
(Supplementary Fig. 8A and B). This was conﬁrmed by
measuring the levels of the ubiquitously expressed glucose
transporter 1 (GLUT1), which is responsible for glucose
uptake in astrocytes and glucose transporter 5 (GLUT5),
which is responsible for fructose uptake (Jurcovicova,
2014). No difference was found between C9orf72 induced
astrocytes and controls in GLUT1 levels indicating that
the C9orf72 induced astrocytes were not starved of
saccharide-based cytoplasmic energy substrates
(Supplementary Fig. 8D–G). Similar results were found
with GLUT5 with or without fructose supplementation,
indicating that the fructose metabolism defect observed
was not due to a loss of fructose transport or a defect in
transporter upregulation in the C9orf72 induced astrocytes.
Pyruvic acid and lactic acid are transported across cell
membranes, including both the plasma and mitochondrial
membranes, by monocarboxylate transporters (Halestrap,
2012a, b). Altered gene expression of monocarboxylate
transporter 4, (SLC16A4) has been found in the spinal
cord of hSOD1G93A mice (Ferraiuolo et al., 2011a) and
the oligodendrocytic lactate transporter monocarboxylate
transporter 1 (SLC16A1) was decreased in the spinal
cords of ALS cases and SOD1G93A mice (Lee et al.,
2012b; Philips et al., 2013). The Krebs cycle intermediates
that we found were affected, can be taken up from blood
by the SLC13 transporters NaDC1, NaDC3 and NaCT.
NaDC3 has been shown to translocate alpha-ketoglutaric
acid (Kaufhold et al., 2011), but at this point this enzyme
has not been linked to ALS.
In saponin-permeabilized cells no signiﬁcant NADH pro-
duction differences were observed between controls and
C9orf72 induced astrocytes in the presence of pyruvic
acid, lactic acid, succinic acid and L-malic acid.
Furthermore, C9orf72 induced astrocytes displayed altered
saponin sensitivity compared to controls (Fig. 3). As sap-
onin functions mainly by solubilizing cholesterol, forming a
complex and leaving the membrane intact (Jacob et al.,
1991; Bottger and Melzig, 2013), this may suggest a po-
tential alteration in the cholesterol content in induced astro-
cyte membranes from C9orf72 ALS cases, which may
inﬂuence the transport of metabolites in the cell, rather
than an enzyme defect. Altered membrane cholesterol con-
tent has previously been observed in ALS cases and models
of disease (Cutler et al., 2002; Baker et al., 2015).
Conversely, a more recent study found no cholesterol con-
tent differences in cortical neuron cultures from wild-type
and G93A SOD1 mice, but did identify an altered suscep-
tibility to cholesterol depletion in terms of loss of NMDA
receptor evoked currents (Antonini et al., 2018).
Cholesterol content has been shown to inﬂuence the phys-
ical properties of membranes including ﬂuidity and rigidity,
which may affect the level of both membrane receptor ex-
pression internalization, and transporter activity (Yeagle
et al., 1988; Ikonen, 2008; Jaipuria et al., 2018; Zhang
et al., 2019). Therefore, in-depth analysis of metabolic sub-
strate transporters within both the plasma and mitochon-
drial membranes and analysis of cholesterol content has the
potential to highlight either chemical or genetic manipula-
tion strategies, which may contribute to enhancing astro-
cyte metabolic ﬂexibility and increasing support to motor
neurons. Intriguingly, the defects in mitochondrial energy
substrate usage identiﬁed in the C9orf72 induced astrocytes
may account for the subtle shift towards a more glycolytic
ATP production state in the C9orf72 induced astrocytes,
described in our previous manuscript (Allen et al., 2019).
In addition to glycogen, we have identiﬁed a defect in
fructose metabolism that may be linked to alterations in
the methyglyoxal removal pathway. Fructose is increasingly
16 | BRAIN 2019: 0; 1–20 S. P. Allen et al.
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prevalent in the human diet as, along with glucose, it is a
component of sucrose, which is used as an artiﬁcial sweet-
ener (Aragno and Mastrocola, 2017). A high-fructose diet
has been associated with insulin resistance and dyslipidae-
mia, as well as causing inﬂammation and reduction of per-
oxisome proliferator-activated receptor alpha (PGC1A) in
animal models (Livesey and Taylor, 2008; Miller and
Adeli, 2008; Mock et al., 2017). As fructose enters glycoly-
sis at DHAP and GAP, it bypasses phosphofructokinase,
the glycolytic rate-limiting enzyme and the need for insulin.
Enhanced exposure to fructose, combined with defects in
the fructose metabolic pathway, may lead to enhanced pro-
tein glycation through accumulation of DHAP and GAP as
well as enhanced methylglyoxal production (Hamada et al.,
1996). Accumulation of toxic AGEs has been linked to
mitochondrial dysfunction and oxidative stress in several
neurodegenerative diseases including Parkinson’s disease
(Seneff et al., 2011; Li et al., 2012; Hipkiss, 2014;
Mastrocola et al., 2016) and in ALS (Kaufmann et al.,
2004; Juranek et al., 2015, 2016; Kim et al., 2018).
Currently there are limited data focusing on methylglyoxal
and its removal in ALS (Sirangelo et al., 2016) and to the
best of our knowledge, this is the ﬁrst study to suggest that
GLO1 levels are altered in ALS patient-derived cell models.
However, the fact that we found similar alterations in the
GLO1 levels in SALS induced astrocytes and sporadic
Parkinson’s disease cases suggests that an important novel
common mechanism of dysfunction may exist between ALS
and Parkinson’s disease. Recently, the protein sensor DJ-1,
implicated in Parkinson’s disease (Bonifati et al., 2003a, b),
was identiﬁed as having glyoxalase activity (Lee et al.,
2012a) with methylglyoxal moieties leading to its down-
regulation and glycation of -synuclein (Sharma et al.,
2019). This indicates that as with ALS, effective removal
of glycation agents such as methylglyoxal in Parkinson’s
disease is crucial in protecting against oxidative stress and
mitochondrial dysfunction in the CNS, which play key
pathogenic roles in both diseases (Barber and Shaw,
2010; Toyoda et al., 2014; Smith et al., 2017;
Macdonald et al., 2018; Mortiboys et al., 2018;
Dolgacheva et al., 2019).
Our ﬁndings that GLO1 levels are reduced in induced
astrocytes derived from ALS and Parkinson’s patients are
interesting especially in light of the recent ﬁndings that Nrf-
2, a key regulator of oxidative stress that is normally se-
questered and inactivated by the Kelch-like ECH associated
protein 1 (KEAP1), is released and activated by accumula-
tion of methylglyoxal (Bollong et al., 2018). This metabol-
ically regulated communication between metabolism and
the oxidative stress response via methylglyoxal is a key
cellular protection pathway, which would be vital in ALS
and Parkinson’s disease where metabolic dysfunction and
oxidative stress are important players in disease patho-
physiology. Further studies are planned in our laboratory
to investigate the effect of loss of GLO1 on this cellular
protection axis.
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